TY - JOUR
T1 - Basic Science and Pathogenesis
AU - Bhatt, Nemil
AU - Puangmalai, Nicha
AU - Jerez, Cynthia
AU - Shchankin, Nikita
AU - Kayed, Rakez
N1 - Publisher Copyright:
© 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - BACKGROUND: Tauopathies, including Alzheimer's Disease and Frontotemporal Dementia, are characterized as intracellular lesions composed of aggregated tau proteins. Soluble tau oligomers are shown to be one of the most toxic species and are responsible for the spread of tau pathology. Recent studies have found that several proteins such as amyloid b, a-synuclein, and TDP-43 can aggregate tau. In this study, we investigated the ability of small metabolites like C9orf72 associated dipeptide protein repeats (DPRs) to interact with and aggregate tau to form toxic soluble tau oligomers. METHOD: We have developed various models which express dipeptide protein repeats to understand the interaction between short peptides and tau. The dipeptide protein repeat induced tau aggregates were characterized using biophysical, as well as biochemical assays in vitro and in cellular models. Furthermore, we evaluated their toxicity, and seeding potency to understand the biological effects of this interaction. RESULT: Our results suggest the propensity for DPRs, especially glycine-arginine and proline-arginine repeats to form oligomeric structures which interact and seed tau in a prion like fashion. This leads to the production of tau oligomers causing alterations in the microtubule dynamics in cell lines as well as primary neuronal culture systems. CONCLUSION: Many studies have investigated the toxicity of small protein repeats, however, the role of DPR oligomers in inducing tau aggregation is still unclear. Thus, the ability to understand the toxic interplay between small peptide repeats and tau oligomers has great potential to further the understanding of tau progression and aid in the development of targeted therapeutics.
AB - BACKGROUND: Tauopathies, including Alzheimer's Disease and Frontotemporal Dementia, are characterized as intracellular lesions composed of aggregated tau proteins. Soluble tau oligomers are shown to be one of the most toxic species and are responsible for the spread of tau pathology. Recent studies have found that several proteins such as amyloid b, a-synuclein, and TDP-43 can aggregate tau. In this study, we investigated the ability of small metabolites like C9orf72 associated dipeptide protein repeats (DPRs) to interact with and aggregate tau to form toxic soluble tau oligomers. METHOD: We have developed various models which express dipeptide protein repeats to understand the interaction between short peptides and tau. The dipeptide protein repeat induced tau aggregates were characterized using biophysical, as well as biochemical assays in vitro and in cellular models. Furthermore, we evaluated their toxicity, and seeding potency to understand the biological effects of this interaction. RESULT: Our results suggest the propensity for DPRs, especially glycine-arginine and proline-arginine repeats to form oligomeric structures which interact and seed tau in a prion like fashion. This leads to the production of tau oligomers causing alterations in the microtubule dynamics in cell lines as well as primary neuronal culture systems. CONCLUSION: Many studies have investigated the toxicity of small protein repeats, however, the role of DPR oligomers in inducing tau aggregation is still unclear. Thus, the ability to understand the toxic interplay between small peptide repeats and tau oligomers has great potential to further the understanding of tau progression and aid in the development of targeted therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85214475892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85214475892&partnerID=8YFLogxK
U2 - 10.1002/alz.093234
DO - 10.1002/alz.093234
M3 - Article
C2 - 39751347
AN - SCOPUS:85214475892
SN - 1552-5260
VL - 20
SP - e093234
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -